End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.13 CNY | -16.01% | -8.28% | -14.78% |
2023 | DR Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
2023 | DR Corporation Limited(XSEC:301177) added to S&P Global BMI Index | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 81.06 times its estimated earnings per share for the ongoing year.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Apparel & Accessories
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.78% | 1.39B | - | ||
-0.79% | 38.29B | C | ||
-12.39% | 13.34B | B+ | ||
+15.09% | 12.52B | A- | ||
+21.16% | 4.49B | - | ||
+22.46% | 2.79B | D+ | ||
+10.03% | 2.52B | - | ||
+3.29% | 1.65B | - | ||
-0.35% | 1.04B | - | - | |
-20.84% | 1.03B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301177 Stock
- Ratings DR Corporation Limited